ADBRY™ (tralokinumab-ldrm) for moderate-to-severe atopic dermatitis

For adults with uncontrolled moderate-to-severe atopic dermatitis¹

When topical prescription therapies only go so far

Not an actual patient.
Individual results may vary.

See Proven Clinical Study Results

Efficacy and safety results from three randomized, double-blind, placebo-controlled trials

See Results

Discover How Adbry Works

The first and only biologic to specifically target and
neutralize IL-13

Explore MOA

Learn About Access & Patient Support

Comprehensive patient support services through the Adbry™ Advocate™ Program including Nurse Advocate and Adbry™ Copay Program. Restrictions apply

Learn More

The first and only biologic developed to specifically target and neutralize IL-13 ¹
Adbry demonstrated long-term safety through 52 weeks ¹
Adbry demonstrated significant skin clearance, improvements in lesion extent and severity, and itch relief at week 16 ^1-4
The flexibility to treat with every-other-week dosing or every-4-week dosing after 16 weeks of treatment (for patients with body weight <100 kg who achieve clear or almost clear skin)¹
Adbry achieved lasting disease control at Weeks 32 and 52 ¹

Adbry has no boxed warning and no requirement for initial lab testing of ongoing lab monitoring in the Prescribing Information

References: 1. Adbry Prescribing Information, LEO Pharma. 2. Silverberg JI, Toth D, Bieber T, et al; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450-463. 3. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. doi:10.1111/bjd.19574. 2021. 4. Data on File. LEO Pharma.

View all

INDICATION AND IMPORTANT SAFETY INFORMATION

ADBRY™ (tralokinumab-ldrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis and angioedema have occurred after administration of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy.
Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.
Parasitic (Helminth) Infections: Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue treatment with ADBRY until the infection resolves.
Risk of Infection with Live Vaccines: ADBRY may alter a patient’s immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ADBRY, complete all age appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients treated with ADBRY. Limited data are available regarding coadministration of ADBRY with non-live vaccines.

ADVERSE REACTIONS:

The most common adverse reactions (incidence ≥1%) are upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown.
Pediatric Use: The safety and effectiveness of ADBRY have not been established in pediatric patients.

Please see Full Prescribing Information.